Evidence map›Paper›PMID 36140394›Full record

ArticleBiomedicines2022

Kynurenine 3-Monooxygenase Interacts with Huntingtin at the Outer Mitochondrial Membrane.

Aisha M Swaih, Carlo Breda, Korrapati V Sathyasaikumar, Natalie Allcock, Mary E W Collier, Robert P Mason, Adam Feasby, Federico Herrera, Tiago F Outeiro, Robert Schwarcz and 2 more

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Huntingtin Interacting Proteins and Pathological Implications.International journal of molecular sciences · 2023
    Review
  5. Neuroprotection by Drugs, Nutraceuticals and Physical Activity.International journal of molecular sciences · 2023
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 4 countries.

Aisha M SwaihDepartment of Genetics and Genome Biology, University of Leicester, Leicester LE1 7RH, UK.
Carlo BredaDepartment of Genetics and Genome Biology, University of Leicester, Leicester LE1 7RH, UK.
Korrapati V SathyasaikumarMaryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Natalie AllcockCore Biotechnology Services, Adrian Building, University of Leicester, University Road, Leicester LE1 7RH, UK.
Mary E W CollierDepartment of Genetics and Genome Biology, University of Leicester, Leicester LE1 7RH, UK.
Robert P MasonDepartment of Genetics and Genome Biology, University of Leicester, Leicester LE1 7RH, UK.
Adam FeasbyDepartment of Genetics and Genome Biology, University of Leicester, Leicester LE1 7RH, UK.
Federico HerreraCell Structure and Dynamics Laboratory, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Lisbon, 1749-016 Lisbon, Portugal.ORCID 0000-0002-9596-9353
Tiago F OuteiroDepartment of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, 37073 Göttingen, Germany.ORCID 0000-0003-1679-1727
Robert SchwarczMaryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Mariaelena RepiciDepartment of Genetics and Genome Biology, University of Leicester, Leicester LE1 7RH, UK.
Flaviano GiorginiDepartment of Genetics and Genome Biology, University of Leicester, Leicester LE1 7RH, UK.
University of Leicester · GBUniversity of Maryland, Baltimore · USGerman Center for Neurodegenerative Diseases · DEUniversity of Lisbon · PT

Funding

The Effects of Kynurenine Aminotransferase Inhibition in People with SchizophreniaP50MH103222 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI SCHWARCZ, ROBERT · 2014 to 2023
$25.2M
Medical Research Council MR/L003503/1Medical Research Council MR/N00373X/1Medical Research Council MR/R011621/1NIMH NIH HHS P50 MH103222
6 · The paper itself

Abstract

The flavoprotein kynurenine 3-monooxygenase (KMO) is localised to the outer mitochondrial membrane and catalyses the synthesis of 3-hydroxykynurenine from L-kynurenine, a key step in the kynurenine pathway (KP) of tryptophan degradation. Perturbation of KP metabolism due to inflammation has long been associated with the pathogenesis of several neurodegenerative disorders, including Huntington's disease (HD)-which is caused by the expansion of a polyglutamine stretch in the huntingtin (HTT) protein. While HTT is primarily localised to the cytoplasm, it also associates with mitochondria, where it may physically interact with KMO. In order to test this hypothesis, we employed bimolecular fluorescence complementation (BiFC) and found that KMO physically interacts with soluble HTT exon 1 protein fragment in living cells. Notably, expansion of the disease-causing polyglutamine tract in HTT leads to the formation of proteinaceous intracellular inclusions that disrupt this interaction with KMO, markedly decreasing BiFC efficiency. Using confocal microscopy and ultrastructural analysis, we determined KMO and HTT localisation within the cell and found that the KMO-HTT interaction is localized to the outer mitochondrial membrane. These data suggest that KMO may interact with a pool of HTT at the mitochondrial membrane, highlighting a possible physiological role for mitochondrial HTT. The KMO-HTT interaction is abrogated upon polyglutamine expansion, which may indicate a heretofore unrecognized relevance in the pathogenesis of this disorder.

Indexed as

BiFChuntingtinHuntington’s diseasekynurenine 3-monooxygenaselive cell imagingmitochondria

Identifiers

PMID36140394
PMCPMC9496550
OpenAlexW4296097328

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.